Nymox Pharmaceutical Corp
NYMX
NYMX was delisted on the 6th of July, 2023.
49 hedge funds and large institutions have $16.5M invested in Nymox Pharmaceutical Corp in 2018 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 23 increasing their positions, 5 reducing their positions, and 2 closing their positions.
360% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 5
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
2% more funds holding
Funds holding: 48 → 49 (+1)
7% less capital invested
Capital invested by funds: $17.8M → $16.5M (-$1.3M)
83% less call options, than puts
Call options by funds: $492K | Put options by funds: $2.89M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$1.15M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$351K |
| 3 |
Simplex Trading
Chicago,
Illinois
|
+$220K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$195K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$168K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Group One Trading
Chicago,
Illinois
|
-$146K |
| 2 |
WS
Wedbush Securities
Los Angeles,
California
|
-$108K |
| 3 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$49K |
| 4 |
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
|
-$31K |
| 5 |
BNP Paribas Financial Markets
Paris,
France
|
-$24.1K |
NYMX Hedge Fund Activity: Q2 2018 in Review
49 of the 4,369 institutional investors tracked by Wall St. Rank reported a position in Nymox Pharmaceutical Corp (NYMX) for Q2 2018, worth a combined $16.5M — down 7.3% from $17.8M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new NYMX positions and 2 closed out — a net gain of 1 holder — while 23 added to existing stakes and 5 trimmed.
The largest buyer was BlackRock, adding an estimated $1.15M. The largest seller was Group One Trading, cutting an estimated $146K.
- 49 institutional investors held Nymox Pharmaceutical Corp (NYMX) as of Q2 2018, up from 48 in Q1 2018.
- Funds reported $16.5M of Nymox Pharmaceutical Corp stock for Q2 2018, down 7.3% quarter-over-quarter.
- 3 funds opened new Nymox Pharmaceutical Corp positions in Q2 2018 and 2 closed out, a net change of +1 holder.
- The largest Nymox Pharmaceutical Corp buyer in Q2 2018 was BlackRock, an estimated $1.15M added.
- The largest Nymox Pharmaceutical Corp seller in Q2 2018 was Group One Trading, an estimated $146K sold.
Based on aggregated 13F filings for Q2 2018.